Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors

Trial Profile

Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs APX 005M (Primary)
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Apexigen
  • Most Recent Events

    • 31 Oct 2017 According to an Apexigen media release, data from the study will be presented as a late-breaking oral presentation at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
    • 18 May 2017 Planned number of patients changed from 32 to 50.
    • 18 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top